APA (7th ed.) Citation

JR, B., JS, L., TE, C., R, B. C., M, N., L, U., . . . SS, R. (2023). Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 41(6), 1200. https://doi.org/10.1200/JCO.22.01503

Chicago Style (17th ed.) Citation

JR, Brahmer, et al. "Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 41, no. 6 (2023): 1200. https://doi.org/10.1200/JCO.22.01503.

MLA (9th ed.) Citation

JR, Brahmer, et al. "Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 41, no. 6, 2023, p. 1200, https://doi.org/10.1200/JCO.22.01503.